Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) ...

Sun Pharma has offered to pay $14 a share in an all-cash deal, putting the Indian drugmaker on track to become one of the top ...

Indian generic medicines giant Sun Pharmaceutical Industries is buying the women’s health company Organon in a deal worth $11 ...

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal ...

The transaction creates a combined entity with $12.4 billion in annual revenue, likely positioning Sun among the global ...

Lower valuation, balance sheet strength and asset risks shape the deal; analysts draw contrasts with earlier buys by Indian ...

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term ...

MD Kirti Ganorkar said Organon’s commercial footprint gives Sun Pharma a ready‑made engine to in‑license near‑approval ...

Sun Pharmaceutical Industries is preparing to raise a multibillion debt financing backing a potential bid for US healthcare ...

Shares of womens healthcare company Organon Co (NYSE: OGN) climbed sharply in after-hours trading on Thursday following ...

Days after Sun Pharmaceutical Industries announced its $ 11.75 billion deal to acquire United States-based healthcare company ...

April 26 () - Sun Pharmaceutical Industries said on Sunday it will ‌buy Organon & Co in an ‌all‑cash deal, valuing the U.75 ...